×
AngioDynamics shares  plummeted on Thursday, after the company released its latest guidance for the full-year. The medical devices maker announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million conditional upon Eximo meeting its technical and revenue milestones.  Following the acquisition, AngioDynamics now expects earnings for fiscal 2020 to range between 10 cents and 15 cents a share – a range lower than analysts’ expectation of 26 cents. Angio CEO Jim Clemmer indicated that the acquisition of Eximo would usher in a remarkable, foundational technology for its portfolio  in a way that  transforms  the way caregivers provide treatment to patients with PAD. "The market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices," Clemmer said. Separa
Aerie Pharmaceuticals, Inc.announced that it has initiated the dosing in a phase II study on netarsudil ophthalmic solution in Japan for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Read more...
Recro Pharma, Inc., a specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, posted revenue of $77.3 million and $71.8 million for the years ended December 31, 2018 and 2017, respectively.The increase of $5.5 million in 2018 revenue versus 2017 revenue was due to an increase in product sales to various commercial partners and increased profit sharing, including the impact from the new revenue recognition standard, recognized from one of our commercial partners. “As we await the upcoming review decision from the U.S. Food and Drug Administration (FDA) for intravenous (IV) meloxicam, we are building our commercial infrastructure and preparing for our first potential product launch during 2019,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma.
Previous
10 of 10
Next